We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Advanced to the highest dose level in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersPresented updated preclinical activity of BDC-4182 and key learnings...
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from...
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.06736 | 11.541361113 | 0.58364 | 0.651 | 0.5602 | 172386 | 0.62277498 | CS |
4 | -0.009 | -1.36363636364 | 0.66 | 0.69 | 0.54 | 122293 | 0.60330159 | CS |
12 | -0.0029 | -0.443492888821 | 0.6539 | 0.718 | 0.54 | 142317 | 0.62498085 | CS |
26 | -0.109 | -14.3421052632 | 0.76 | 0.795001 | 0.54 | 153173 | 0.68273783 | CS |
52 | -0.2419 | -27.091499608 | 0.8929 | 1.56 | 0.54 | 164973 | 0.87233332 | CS |
156 | -9.119 | -93.3367451382 | 9.77 | 10.705 | 0.54 | 199617 | 1.8624044 | CS |
260 | -21.339 | -97.0395634379 | 21.99 | 43.07 | 0.54 | 190054 | 6.64156499 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions